TGF-β and VEGF cooperatively control the immunotolerant tumor environment and the efficacy of cancer immunotherapies. - Wikidata - awgldk - TriplyDB

TGF-β and VEGF cooperatively control the immunotolerant tumor environment and the efficacy of cancer immunotherapies.

TGF-β and VEGF cooperatively control the immunotolerant tumor environment and the efficacy of cancer immunotherapies.

http://www.wikidata.org/entity/Q37277182

about

Local Immune Responsiveness of Mice Bearing Premalignant Oral Lesions to PD-1 Antibody Treatment.VEGF blockade enhances the antitumor effect of BRAFV600E inhibition.Redirecting the focus of cancer immunotherapy to premalignant conditions.Perspective on the dynamics of cancer.An antivascular vaccine to boost self-immunity and strike the tumor Immunotherapy for hepatocellular carcinoma patients: is it ready for prime time?Perspective on immune oncology with liquid biopsy, peripheral blood mononuclear cells, and microbiome with non-invasive biomarkers in cancer patients.Immunogenomic Classification of Colorectal Cancer and Therapeutic Implications.Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models.Role of IL-23 signaling in the progression of premalignant oral lesions to cancer.TGF-β in T Cell Biology: Implications for Cancer Immunotherapy.

P2860

Q33832752-62833596-118F-4D5D-B920-3DDBFD300947 Q37618011-457D4591-45AB-4696-A9B7-5B88764CACA2 Q39107022-5C790D97-E40B-4FF1-AC11-CC58E4114F32 Q42284422-863875E8-5ACD-4662-89B8-7436AF5A7E48 Q42359550-FD6313CD-3C52-4C86-9038-2C9D5A36B244 Q45070547-244DAD90-B042-42B0-9CC4-5B8C8F053C81 Q47219905-3F0F6814-3202-4A1F-855F-0423667EFD35 Q47323319-CAD5C188-8A61-4191-B3C9-7B59B3407414 Q54111915-A1FC161F-81A0-4F9F-99CA-E56822427DC0 Q55265890-E432C06D-65EE-48E2-837E-3BB73F798118 Q55515390-E2917DB6-C381-4D26-A197-211AEB14E7FE

P2860

TGF-β and VEGF cooperatively control the immunotolerant tumor environment and the efficacy of cancer immunotherapies.

http://www.wikidata.org/entity/Q37277182

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 16 June 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

TGF-β and VEGF cooperatively c ...... acy of cancer immunotherapies.

@en

TGF-β and VEGF cooperatively c ...... acy of cancer immunotherapies.

@nl

type

label

TGF-β and VEGF cooperatively c ...... acy of cancer immunotherapies.

@en

TGF-β and VEGF cooperatively c ...... acy of cancer immunotherapies.

@nl

prefLabel

TGF-β and VEGF cooperatively c ...... acy of cancer immunotherapies.

@en

TGF-β and VEGF cooperatively c ...... acy of cancer immunotherapies.

@nl

P1433

Q37277182-DEC588EB-7B12-43E7-8088-CEA44546675D

P1476

Q37277182-FD74098C-96EC-49EE-8B30-E0D2786A2121

P2093

Q37277182-7091BD91-097F-4551-BC36-DAC831CFEB35

Q37277182-B73DCC07-0D34-4BBD-A0CE-98FB1F013A84

Q37277182-BD63DE41-F80D-43E9-AF2F-4000A3D4DE10

Q37277182-F72A29B9-1951-4F60-B900-539E1E7BCBD2

P2860

Q37277182-0276DF04-78A2-4081-9A91-C43873C8DBC2

Q37277182-05A3211F-5B6F-41C1-A372-99CA83494C88

Q37277182-06C0B476-08E8-4CF2-B243-32CE6CFE6975

Q37277182-08EBEA64-BFB4-43DC-8EA4-EAC057822761

Q37277182-0974677B-3E4E-4AEC-AAC5-C0DCC166290D

Q37277182-0F0185BE-AEFF-4870-90B6-E26BCB488937

Q37277182-1D7E7D5C-4511-48A4-A9CE-23C648538BAF

Q37277182-1DBE21AA-2DDC-4AF6-9CD2-9D9EDFD1EE1D

Q37277182-242622A2-F94D-4F1D-9B16-26AA56981CD7

Q37277182-2A67A926-28B1-4EB2-839C-6E6196D7E339

P304

Q37277182-080FF8AC-BD4C-4841-84A5-EE899AEA6781

P31

Q37277182-9E5AF86E-A655-415D-BDC6-F328D3B9156F

P356

Q37277182-AB577CD3-E36D-42CD-A05F-D8F59E579D62

P433

Q37277182-C1BEF6BA-D445-407D-9317-D0B8C9C028B5

P478

Q37277182-CB130C3C-13DF-4571-B95F-7535A1E5CBEF

P50

Q37277182-65E230DF-FAAA-4138-872F-E2C51D4DF585

Q37277182-81E9095E-5A35-4EA4-B05B-9AF809FADDAF

Q37277182-8D510E86-BB84-4EC2-8D9D-456DC40357C7

Q37277182-90D89A1E-61E3-4444-8B50-70D5DD42AEA3

P577

Q37277182-7980A33B-121C-42A1-97FC-83BF45E78569

P698

Q37277182-878319AD-923F-4041-9E82-657DC9DD1276

P921

Q37277182-D976E2DB-54BD-437A-97EF-D6B9E1B420E9

P932

Q37277182-97443EDE-9FFF-40B3-921F-73B2B92BA546

P356

JCI.INSIGHT.85974

P1433

P1476

TGF-β and VEGF cooperatively c ...... acy of cancer immunotherapies.

@en

P2093

Béatrice Levacher

http://www.w3.org/2001/XMLSchema#string

Faustine Brimaud

http://www.w3.org/2001/XMLSchema#string

Laura Florez

http://www.w3.org/2001/XMLSchema#string

Thomas Vazquez

http://www.w3.org/2001/XMLSchema#string

P2860

The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function

Cytoscape: a software environment for integrated models of biomolecular interaction networks

Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

Nivolumab plus ipilimumab in advanced melanoma.

Immunity, Inflammation, and Cancer

Immune checkpoint blockade: a common denominator approach to cancer therapy

Type, density, and location of immune cells within human colorectal tumors predict clinical outcome

TGFbeta in Cancer

In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector

Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival

P304

e85974

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1172/JCI.INSIGHT.85974

http://www.w3.org/2001/XMLSchema#string

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

1

http://www.w3.org/2001/XMLSchema#string

P50

David Klatzmann

Bertrand Bellier

Djamel Nehar-Belaid

P577

2016-06-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27699271

http://www.w3.org/2001/XMLSchema#string

P921

P932

5033816

http://www.w3.org/2001/XMLSchema#string